876 related articles for article (PubMed ID: 16912303)
21. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents.
Fooks AR; Jeevarajah D; Lee J; Warnes A; Niewiesk S; ter Meulen V; Stephenson JR; Clegg JC
J Gen Virol; 1998 May; 79 ( Pt 5)():1027-31. PubMed ID: 9603317
[TBL] [Abstract][Full Text] [Related]
22. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005.
Atrasheuskaya AV; Kulak MV; Neverov AA; Rubin S; Ignatyev GM
Vaccine; 2008 Apr; 26(17):2111-8. PubMed ID: 18343536
[TBL] [Abstract][Full Text] [Related]
23. Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.
Julik E; Reyes-Del Valle J
J Virol; 2016 Jun; 90(11):5270-5279. PubMed ID: 26984727
[TBL] [Abstract][Full Text] [Related]
24. Experimental measles. II. Infection and immunity in the rhesus macaque.
Zhu YD; Heath J; Collins J; Greene T; Antipa L; Rota P; Bellini W; McChesney M
Virology; 1997 Jun; 233(1):85-92. PubMed ID: 9229928
[TBL] [Abstract][Full Text] [Related]
25. V and C proteins of measles virus function as virulence factors in vivo.
Patterson JB; Thomas D; Lewicki H; Billeter MA; Oldstone MB
Virology; 2000 Feb; 267(1):80-9. PubMed ID: 10648185
[TBL] [Abstract][Full Text] [Related]
26. The recombinant globular head domain of the measles virus hemagglutinin protein as a subunit vaccine against measles.
Lobanova LM; Eng NF; Satkunarajah M; Mutwiri GK; Rini JM; Zakhartchouk AN
Vaccine; 2012 Apr; 30(20):3061-7. PubMed ID: 22406109
[TBL] [Abstract][Full Text] [Related]
27. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.
Polack FP; Hoffman SJ; Crujeiras G; Griffin DE
Nat Med; 2003 Sep; 9(9):1209-13. PubMed ID: 12925847
[TBL] [Abstract][Full Text] [Related]
28. Immune response to measles vaccine in 6 month old infants in Papua New Guinea.
Kurubi J; Vince J; Ripa P; Tefuarani N; Riddell M; Duke T
Trop Med Int Health; 2009 Feb; 14(2):167-73. PubMed ID: 19171008
[TBL] [Abstract][Full Text] [Related]
29. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
Wild TF; Bernard A; Spehner D; Drillien R
J Gen Virol; 1992 Feb; 73 ( Pt 2)():359-67. PubMed ID: 1538193
[TBL] [Abstract][Full Text] [Related]
30. Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector.
Kovarik J; Gaillard M; Martinez X; Bozzotti P; Lambert PH; Wild TF; Siegrist CA
Virology; 2001 Jun; 285(1):12-20. PubMed ID: 11414801
[TBL] [Abstract][Full Text] [Related]
31. Role of CD46 in measles virus infection in CD46 transgenic mice.
Blixenkrone-Møller M; Bernard A; Bencsik A; Sixt N; Diamond LE; Logan JS; Wild TF
Virology; 1998 Sep; 249(2):238-48. PubMed ID: 9791016
[TBL] [Abstract][Full Text] [Related]
32. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody.
Polack FP; Auwaerter PG; Lee SH; Nousari HC; Valsamakis A; Leiferman KM; Diwan A; Adams RJ; Griffin DE
Nat Med; 1999 Jun; 5(6):629-34. PubMed ID: 10371500
[TBL] [Abstract][Full Text] [Related]
33. Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay.
Hamkar R; Mahmoodi M; Nategh R; Jelyani KN; Eslami MB; Mohktari-Azad T
East Mediterr Health J; 2006 Nov; 12(6):775-82. PubMed ID: 17333822
[TBL] [Abstract][Full Text] [Related]
34. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.
Stittelaar KJ; Wyatt LS; de Swart RL; Vos HW; Groen J; van Amerongen G; van Binnendijk RS; Rozenblatt S; Moss B; Osterhaus AD
J Virol; 2000 May; 74(9):4236-43. PubMed ID: 10756037
[TBL] [Abstract][Full Text] [Related]
35. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.
Chabot S; Brewer A; Lowell G; Plante M; Cyr S; Burt DS; Ward BJ
Vaccine; 2005 Feb; 23(11):1374-83. PubMed ID: 15661386
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing B cell response in measles.
Bouche FB; Ertl OT; Muller CP
Viral Immunol; 2002; 15(3):451-71. PubMed ID: 12479395
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of retroviral infection in vitro by anti-Le(y) IgG: reversal by humanization of monoclonal mouse antibody.
Hansen JE; Sørensen AM; Arendrup M; Olofsson S; Nielsen JO; Janzek E; Nielsen C; Loibner H
APMIS; 1993 Sep; 101(9):711-8. PubMed ID: 7902106
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses.
Hoffman SJ; Polack FP; Hauer DA; Singh M; Billeter MA; Adams RJ; Griffin DE
J Infect Dis; 2003 Nov; 188(10):1553-61. PubMed ID: 14624382
[TBL] [Abstract][Full Text] [Related]
39. Characterization of measles virus-specific cytotoxic antibodies by use of a chronically infected cell line.
Ehrnst AC
J Immunol; 1975 Mar; 114(3):1077-82. PubMed ID: 1089724
[TBL] [Abstract][Full Text] [Related]
40. Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells.
Fujinami RS; Norrby E; Oldstone MB
J Immunol; 1984 May; 132(5):2618-21. PubMed ID: 6546943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
